Ozempic / GLP-1
OpenACTIVECausation
Plaintiffs allege GLP-1 receptor agonists cause severe gastroparesis (stomach paralysis), bowel obstruction, and pancreatitis. FDA added gastroparesis warning to labels in 2023. Studies show delayed gastric emptying is a known mechanism of GLP-1 drugs, with some patients experiencing permanent gastrointestinal damage.
Defendants
| Entity | Role | Note |
|---|---|---|
| Novo Nordisk | Manufacturer | Ozempic, Wegovy, Rybelsus (semaglutide) |
| Eli Lilly | Manufacturer | Mounjaro, Zepbound (tirzepatide) |
Litigation Timeline
Intelligence Signals
This proposed rule would revise the Medicare Advantage (Part C), Medicare Prescription Drug Benefit (Part D), Medicaid, Medicare cost plan, and Programs of All-Inclusive Care for the Elderly (PACE) regulations to implement changes related to Star Ratings, marketing and communications, agent/broker compensation, health equity, drug coverage, dual eligible special needs plans (D-SNPs), utilization management, network adequacy, and other programmatic areas, including the Medicare Drug Price Negotia
Derington CG et al.. JAMA network open. 2025 Oct 1.
Crisafulli S et al.. Annals of internal medicine. 2026 Jan.
Keng C et al.. Cureus. 2025 Dec.
Vlaeminck N et al.. Anaesthesia. 2026 Feb 3.
Triumbari EKA et al.. Clinical nuclear medicine. 2026 Feb 3.
Key Facts
- Status
- active
Geographic Exposure
Eligibility Criteria
- ✓Used Ozempic, Wegovy, Mounjaro, or other GLP-1 drug
- ✓Diagnosed with gastroparesis, bowel obstruction, or severe GI injury
- ✓Injury occurred during or after GLP-1 drug use
- ✓Required hospitalization or surgical intervention